Drug details:
Molecular formula: C₁₆H₁₀Br₂F₃N₃O₂S

Standard name: 2-[(2E)-2-[(3,5-dibromo-2-hydroxyphenyl)methylidene]hydrazinyl]-2-sulfanylidene-N-[3-(trifluoromethyl)phenyl]acetamide

Curated SMILES: O=C(NC1=CC=CC(C(F)(F)F)=C1)C(=S)N/N=C/C1=CC(Br)=CC(Br)=C1O

Evidence for compound's anti-virulence activity:

Chlamydia
Related VF: TTSS (Type III secretion system)
Target: Not determined
Drug effect: Inhibits T3SS activity and disrupts progression of the chlaymdial development cycle.
Max phase: Preclinical (in vitro)
Publication:
Zigangirova NA, et al., 2012. Development of Chlamydial Type III Secretion System Inhibitors for Suppression of Acute and Chronic Forms of Chlamydial Infection. Acta Naturae 4(2):87-97.